TL;DR
This paper presents the first atomic-level crystal structures of properdin (FP) and its complexes with the complement system's C3 convertase. These structures reveal how FP oligomerizes and binds to the convertase, explaining its role as a crucial positive regulator of innate immunity and providing a molecular basis for understanding FP-related deficiencies.
What Problem Does This Paper Address?
The complement system is a vital part of our innate immune defense, acting as a cascade of proteins that can be activated through three main pathways: classical, lectin, and alternative. The alternative pathway (AP) is particularly important for recognizing and eliminating pathogens and damaged host cells. A key player in the AP is the C3 convertase (C3bBb), which amplifies the complement response. Properdin (FP) is known to be a positive regulator of this C3 convertase, enhancing its activity. However, despite its known importance, the precise molecular mechanisms by which FP binds to the convertase, how it oligomerizes to form its characteristic polydisperse structures, and how these interactions lead to enhanced convertase activity remained largely unknown. This lack of structural understanding hindered the development of targeted therapeutics and a deeper comprehension of FP's role in various diseases and its potential involvement in pattern recognition.
Methods
The researchers employed a multi-pronged approach combining structural biology, biochemistry, and biophysics.
- X-ray Crystallography: This was the cornerstone technique, used to determine the high-resolution 3D structures of:
- The functional properdin monomer (FPc).
- A truncated properdin construct (FPCA3).
-
Complexes of FP with the C3 convertase (C3bBb) and stabilizing proteins (SCIN and a nanobody hFPNb1). This allowed for detailed visualization of protein-protein interactions and structural domains.
-
Molecular Dynamics (MD) Simulations: Microsecond-long MD simulations of C3 and C3b were performed to understand the dynamic differences between these two crucial complement components, particularly in regions relevant to FP binding.
- Biochemical Assays:
- Size Exclusion Chromatography (SEC): Used to assess the formation of stable complexes between FP fragments and the proconvertase, and to analyze the oligomeric state of purified FP.
- SDS-PAGE: Employed to analyze the products of FH-assisted FI cleavage of C3b, assessing the impact of FP on this regulatory step.
- Bio-Layer Interferometry (BLI): A label-free technique used extensively to quantify the binding affinities and kinetics of interactions between FP variants and C3b, as well as FP and the C3bB proconvertase. This was crucial for validating structural findings and assessing the functional impact of mutations.
- Mass Spectrometry: Used to confirm the disulfide bridge patterns within the properdin protein, particularly in the TB domain.
- Western Blotting: Utilized to analyze protein expression and secretion of FP variants in cell supernatants and pellets, aiding in the study of FP folding and oligomerization.
Datasets
Not explicitly discussed as "datasets" in the traditional machine learning sense. The study relies on:
- Existing Protein Data Bank (PDB) entries: Crystal structures of C3 (2A73) and C3b (5FO79) were used as starting points for molecular dynamics simulations.
- Newly determined crystal structures: The paper reports novel crystal structures of FP (FPc, FPCA3) and FP-convertase complexes.
- Biophysical data: Binding data from BLI experiments and SEC profiles serve as the primary "data" for validating functional hypotheses.
Key Insights and Ideas
- FP Oligomerization Architecture: FP forms oligomers through two primary interfaces: one involving the TB domain and TSR4 of adjacent monomers, and a larger one involving TSR1 and TSR6. This explains the extended, polydisperse nature of FP observed previously.
- Convertase Binding Site Defined: The core binding site for the C3 convertase is located on FP's TSR5 and TSR6 domains, specifically interacting with the C-terminal region of C3b and the Bb subunit.
- Mechanism of Convertase Stabilization: FP stabilizes the C3 convertase by binding to the C-terminus of C3b, which in turn stabilizes the interaction with the Mg<sup>2+</sup>-bound MIDAS site in the Bb protease. This is proposed to underlie FP's role in enhancing convertase activity.
- FP's Role in C3b Degradation Inhibition: FP directly competes with Factor I (FI) for binding to C3b, thereby inhibiting the degradation of C3b to iC3b. This is a key mechanism by which FP promotes complement amplification.
- Structural Basis for FP Deficiencies: The structures provide a molecular explanation for various FP deficiencies, linking specific mutations to altered oligomerization, reduced binding affinity to C3b, and ultimately, impaired complement activation.
- FP Specificity for C3b over C3: Differences in the dynamics and conformation of the C3b C345c domain, particularly around the α2-helix, explain FP's preference for C3b over its precursor, C3.
Key Results
- Atomic Structures: The paper presents the first atomic resolution crystal structures of FP (FPc and FPCA3) and FP-C3 convertase complexes.
- FP Monomer Structure: The FP monomer consists of a TB domain and six thrombospondin repeats (TSRs). TSR5 and TSR6 are crucial for convertase binding.
- Oligomerization Interfaces: Two distinct interfaces were identified for FP oligomerization, involving TB-TSR4 and TSR1-TSR6 interactions between monomers.
- Convertase Binding: FP binds to the C3 convertase primarily through its TSR5 and TSR6 domains, interacting with C3b and Bb.
- Functional Validation: Biophysical experiments (BLI) confirmed the structural findings, demonstrating that mutations in identified binding interfaces or residues involved in FP deficiencies significantly altered FP's binding to C3b and its ability to form stable complexes with the proconvertase.
- FP-FI Competition: FP was shown to directly compete with FI for C3b binding, inhibiting C3b degradation.
- FP Deficiencies Explained: The structures provide a molecular basis for understanding the functional consequences of mutations associated with Type I and Type II FP deficiencies.
Limitations and Future Work
- Resolution of Complex Structures: While providing significant insights, the crystal structures of the FP-convertase complexes were determined at relatively low resolution (6-6.2 Å). This limits the detailed interpretation of some interactions, particularly those involving flexible regions or less ordered components.
- Dynamic Nature of Oligomers: The study acknowledges that FP exists as a polydisperse mixture of oligomers. While the structures provide models for dimer formation and oligomerization interfaces, the full dynamic range and precise architecture of all oligomeric states in solution remain areas for further investigation.
- In Vivo Relevance of Specific Interactions: While structural and biochemical data strongly support the proposed mechanisms, further in vivo studies are needed to fully elucidate the physiological relevance of all identified interactions and the precise role of FP in pattern recognition and its interaction with NKp46.
- Therapeutic Development: The authors suggest that the detailed structural information provides a foundation for developing targeted FP inhibitors or modulators, which could be a significant avenue for future therapeutic research.
- FP's Role in C5 Convertases: The paper touches upon FP's potential role in C5 convertases but notes that these complexes are difficult to reconstitute in soluble form, suggesting that further structural studies using cryo-EM of vesicles might be necessary.
Summary updated